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26 Abstract
27 Alveolar echinococcosis is a neglected parasitic zoonosis caused by 
28 Echinococcus multilocularis. The pharmacological treatment is based on albendazole 
29 (ABZ). However, the low water solubility of the drug produces a limited dissolution 
30 rate, with the consequent failure in the treatment of the disease. Solid dispersions are a 
31 successful pharmacotechnical strategy to improve the dissolution profile of poorly water 
32 soluble drugs. The aim of this work was to determine the in vivo efficacy of ABZ solid 
33 dispersions using poloxamer 407 as a carrier (ABZ:P407 SDs) in the murine 
34 intraperitoneal infection model for secondary alveolar echinococcosis. In the 
35 chemoprophylactic efficacy study, the ABZ suspension, the ABZ:P407 SDs and the 
36 physical mixture of ABZ and poloxamer 407 showed a tendency to decrease the 
37 development of murine cysts, causing damage to the germinal layer. In the clinical 
38 efficacy study, the ABZ:P407 SDs produced a significant decrease in the weight of 
39 murine cysts. In addition, the SDs produced extensive damage to the germinal layer. 
40 The increase in the efficacy of ABZ could be due to the improvement of water solubility 
41 and wettability of the drug due to the surfactant nature of poloxamer 407. In conclusion, 
42 this study is the basis for further research. This pharmacotechnical strategy might in the 
43 future offer novel treatment alternatives for human alveolar echinococcosis.
44
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49 Key Findings
50 - Albendazole (ABZ) solid dispersions showed higher efficacy than ABZ against
51 murine alveolar echinococcosis.
52 - This is a consequence of the increase in the dissolution rate of ABZ that could
53 impact on improvement in bioavailability.
54 - ABZ solid dispersions could represent an alternative strategy for future
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59 Introduction
60 Alveolar echinococcosis (AE) is a severe neglected parasitic zoonosis caused by 
61 the metacestode stage of Echinococcus multilocularis, which represents an important 
62 public health threat. This parasite is predominantly maintained in a wildlife cycle, with 
63 carnivores as definitive hosts and small mammals as intermediate hosts. Humans 
64 acquire the infection by ingesting eggs shed in the feces of a definitive host and develop 
65 the metacestode stage, which is characterised by a tumour-like and infiltrative growth. If 
66 not appropriately treated, parasite expansion will eventually lead to organ failure and 
67 death of the patient (Kern et al., 2017).
68 The metacestode stage is composed of numerous small vesicles with a wall 
69 structure formed by an outer acellular laminated layer and an internal cellular layer 
70 called germinal layer (Eckert and Deplazes, 2004). A special cell type in the germinal 
71 layer, the germinative cells, are responsible for the high regenerative potential of the 
72 parasite (Kern et al., 2017).
73 There are several approaches to the management of AE. In patients with viable 
74 cysts, the treatment of choice is the total removal of the cystic lesion combined with 
75 oral treatment with 15 mg/kg/day of albendazole (ABZ) for two years. In inoperable 
76 patients, prolonged treatment with ABZ should be carried out to decrease the 
77 proliferation of E. multilocularis. In cases of calcified or negative lesions by 
78 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET), the patient should 
79 be periodically monitored (watch and wait) (Wen et al., 2019). 
80 For an effective treatment in systemic infections, the drug must be sufficiently 
81 soluble in water to easily reach the cell membrane, but also hydrophobic enough to 
82 cross it (Thompson, 1997). The biopharmaceutical classification system categorizes 
83 ABZ as a class 2 drug due to its low aqueous solubility and high permeability (Kasim et 
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84 al., 2004). These characteristics produce a limited dissolution rate resulting in a poor 
85 and erratic bioavailability of ABZ (Marriner et al., 1986; Edwards and Breckenridge, 
86 1988; Castro et al., 2009). Due to the low concentration of drug reaching the parasite, 
87 ABZ acts as a parasitostatic rather than as a parasitocidal agent for many cases, and the 
88 recurrence rates after interruption of therapy are high (Reuter et al., 2004). 
89 Consequently, the treatment must be carried out with high daily doses of ABZ for 
90 prolonged periods, with the risk of low adherence to the treatment and the possibility of 
91 adverse effects (Bardonnet et al., 2013; Kern et al., 2017). Moreover, another 
92 explanation for the parasitostatic effect of ABZ on germinative cells is that they may 
93 specifically express a β-tubulin isoform with limited affinity to benzimidazoles (Brehm 
94 and Koziol, 2014).
95 The development of new ABZ formulations that improve its solubility is 
96 essential to increase the effectiveness of pharmacological treatment. Until now, several 
97 pharmacotechnical strategies to increase bioavailability and, consequently, the 
98 effectiveness of ABZ have been evaluated in murine models of cystic and alveolar 
99 echinococcosis: incorporation of ABZ into liposomes (Dvorožňáková et al., 2004; Lv et 
100 al., 2012), ABZ loaded in lipid nanocapsules (Pensel et al., 2015; Ullio Gamboa et al., 
101 2019), nanocrystal and nanocrystalline formulations of ABZ (Pensel et al., 2018; Hu et 
102 al., 2019), solid dispersions of ABZ with poloxamer 188 (Pensel et al., 2014) and ABZ-
103 chitosan microspheres (Abulaihaiti et al., 2015).
104 The solid dispersions (SDs) are a successful strategy to improve the dissolution 
105 profile of poorly water soluble drugs. This strategy is currently widely used in 
106 therapeutics, which is reflected in numerous commercialized products. For example, 
107 Sporanox®, Onmel® and Gris-PEG® are used as antifungals, whereas Kaletra®, 
108 Intelence® and Norvir® are indicated in combination with other antiretroviral agents for 
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109 the treatment of HIV. On the other hand, Isoptin SR®, Nivadil®, Afeditab CR® and 
110 Adalat-XL® are indicated for the treatment of heart conditions, Cesamet® is used as 
111 antiemetic and Kalydeco® is indicated for cystic fibrosis (Cid et al., 2019).
112 The SDs are molecular mixtures of drugs and inert carriers, prepared by the 
113 fusion method and/or solvent method (Chiou and Riegelman, 1971).  According to the 
114 physical state of the carrier, SDs are classified into four generations (Vasconcelos et al, 
115 2007). In the third generation of SDs, surfactants or emulsifiers are used as carriers, 
116 which improve the dissolution profile and the physical and chemical stability of the 
117 drug (Desai et al., 2006). These SDs were more stable mainly due to a reduction of drug 
118 recrystallization (Vasconcelos et al, 2007).
119 Poloxamers, nonionic surfactants with solubilizing properties, are suitable for 
120 most of the standard procedures used to prepare SDs because of their polymeric nature. 
121 In addition, they are not metabolized in the body (Collett and Popli, 2000). Poloxamer 
122 407 (P407) is accepted by the FDA as an inactive ingredient for different types of 
123 preparations (e.g., intravenous, inhalation, oral solution, suspension, ophthalmic or 
124 topical formulations) (Rowe et al., 2005). Simonazzi et al. (2018) designed ABZ SDs 
125 using P407 as carrier (ABZ:P407 SDs). These SDs markedly improved ABZ solubility 
126 and dissolution rate compared with pure ABZ and a commercial formulation. These 
127 drug-related factors affect the gastrointestinal absorption thus improving the 
128 bioavailability. In this context, the aim of the current work was to determine the in vivo 
129 efficacy of ABZ:P407 SDs in the murine model of AE.
130
131 Materials and methods
132 Preparation of solid dispersions and physical mixtures
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133 The ABZ:P407 SDs were prepared by the fusion method as reported by 
134 Simonazzi et al. (2018) ensuring quality in terms of physicochemical properties and 
135 dose adjustment. Briefly, ABZ (Pharmaceutical grade, Parafarm, Argentina) was 
136 homogeneously dispersed in the molten P407 (BASF®, Germany) at 63 degrees (1:1), 
137 by stirring. The preparation was rapidly cooled in liquid nitrogen, pulverized and 
138 sieved. The 210 μm particle size fraction was kept in a glass vial at room temperature 
139 until use. 
140 Physical mixtures were prepared from ABZ and P407 previously sieved (210 
141 μm particle size fraction). The components were mixed in equal proportions in a 
142 Laboratory-scale V-blender for 5 min. The powders were stored in a glass vial at room 
143 temperature until use.
144
145 Preparation of ABZ formulations
146 The suspension of ABZ (3.08 mg/ml) was prepared by dispersion of pure ABZ 
147 in distilled and deionized water (pH = 7.0) with carboxymethylcellulose (CMC, Todo 
148 Droga, Córdoba, Argentina) (0.5% w/v, pH = 6.0). The suspension was shaken for 5 h 
149 and sonicated for 1 h. The ABZ:P407 SDs (6.16 mg/ml), physical mixture (6.16 mg/ml) 
150 and P407 (3.08 mg/ml) suspensions were prepared by dissolution in distilled and 
151 deionized water (pH = 7.0) under shaking (5 h). All formulations were stored at 4 ºC 
152 and were vigorously shaken before administration to mice.
153
154 Parasite material
155 The studies were carried out using E. multilocularis isolate J2012 (kindly 
156 provided by Klaus Brehm, Institute for Hygiene and Microbiology, University of 
157 Würzburg, Germany). To establish the murine intraperitoneal infection model for 
Page 8 of 26Parasitology
8
158 secondary AE, the parasite was propagated in the peritoneum of CF-1 mice and was 
159 processed as described by Albani et al. (2015), with some modifications. Briefly, the 
160 metacestodes obtained from the peritoneal cavity of the animals were cut to obtain a 
161 parasitic suspension. The suspension was passed through a metallic strainer and washed 
162 several times with phosphate-buffered saline (PBS). Finally, 0.5 vol of PBS and 12 
163 µg/ml of ciprofloxacin (Roemmers, Argentina) were added to parasite tissue and 
164 incubated overnight at 4 ºC (Spiliotis and Brehm, 2009).
165
166 Experimental design and evaluation of in vivo efficacy of ABZ:P407 SDs against the 
167 murine model of AE
168 For chemoprophylactic and clinical efficacy studies, one hundred female CF-1 mice 
169 were intraperitoneally infected with 0.3 ml of homogenized parasitic material  of E. 
170 multilocularis in PBS (n = 50 for each study). In the chemoprophylactic efficacy study, 
171 the dosage of the animals began 1 day post-infection, while in the clinical efficacy study 
172 the treatment began 6 weeks post-infection. In each study, the experimental groups 
173 were: 1- water control group, mice received distilled and deionized water as a placebo; 
174 2- P407 control group, mice received P407 suspended in distilled and deionized water;
175 3- ABZ-CMC group, mice were treated with a suspension of ABZ in distilled and
176 deionized water with CMC; 4- Physical mixture group, the animals received a 
177 suspension of physical mixture (ABZ and P407, 1:1); 5- ABZ:P407 SDs group, animals 
178 were treated with a suspension of ABZ:P407 SDs. The animals were randomly 
179 distributed into the treatment groups (10 animals/group) with 5 mice per cage.
180  In both studies, treatments were performed daily for 30 days by intragastric 
181 administration in a volume of 0.3 ml. For groups 3, 4 and 5 the dose of ABZ was 25 
182 mg/kg per day.
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183 Approximately 10 weeks post-infection, the mice were anesthetized with 100 
184 mg/kg of ketamine and 10 mg/kg of xylazine and subsequently euthanized by cervical 
185 dislocation and necropsied.  The cystic masses were obtained from the peritoneal cavity 
186 of each mouse and weighed. The median cysts weight from each group and 
187 ultrastructural study of the germinal layer of cysts by scanning electron microscopy 
188 were used to determine the efficacy of each treatment (Albani et al, 2015). 
189
190 Scanning electron microscopy
191 Samples of cysts obtained from animals involved in both in vivo efficacy studies 
192 were processed for scanning electron microscopy as described by Elissondo et al. 
193 (2007). Briefly, samples were fixed in 3% glutaraldehyde (Sigma-Aldrich, St. Louis, 
194 USA) in 0.1 M sodium cacodylate buffer pH 7.4 (Sigma-Aldrich, St. Louis, USA) for 
195 72 h at 4°C. Then, several washes in 0.1 M sodium cacodylate buffer were made. After 
196 that, the specimens were dehydrated by sequential incubations of 10 min in increasing 
197 concentrations of ethanol (Cicarelli, Argentina): 50%, 70%, 80%, 90%, 95%, and twice 
198 in 100%. Finally, samples were immersed in hexamethyldisilazane (Sigma-Aldrich, St. 
199 Louis, USA) for 5 min, 1 h, and overnight. They were then sputter-coated with gold 
200 (100-Å thickness) and inspected on a JEOL JSM-6460 LV scanning electron 
201 microscope operating at 15 kV. 
202
203 Statistical analysis
204 Cysts weights of the different groups, reported as median and interquartile range 
205 (IQR), were compared by Kruskal Wallis Test (nonparametric method) followed by 
206 Dunn's Multiple Comparisons Test. The analysis was carried out using Instat 3.0 
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207 software program (GraphPad Software, San Diego, CA, USA). In all cases, P values 
208 less than 0.05 (P < 0.05) were considered statistically significant.
209
210 Results
211 Chemoprophylactic efficacy study of ABZ:P407 SDs against the murine model of AE 
212 All the infected mice belonging to the chemoprophylactic efficacy study 
213 developed cystic masses in the abdominal cavity. No significant differences were found 
214 (P > 0.05) between the median weight of the cysts of the water and P407 control groups. 
215 Although the median weight of cysts recovered from mice treated with all formulations 
216 of ABZ were lower in relation to the control groups, no significant differences were 
217 detected (P > 0.05, Table 1). 
218 The ultrastructural study of the germinal layer of metacestodes recovered from 
219 control and treated groups is shown in Fig. 1. The germinal layer of cysts obtained from 
220 control mice showed the characteristic multicellular structure (Fig. 1a). The decrease in 
221 the weight of the cysts belonging to treated groups was correlated with ultrastructural 
222 alterations observed by scanning electron microscopy. Areas without cells in the 
223 germinal layer were observed in treated cysts (Figs. 1b-d).
224
225 Clinical efficacy study of ABZ:P407 SDs against the murine model of AE
226 Table 2 summarizes the cyst weights (median and IQR) recorded after 
227 treatments of the different experimental groups involved in therapeutic efficacy study. 
228 There were no statistically significant differences (P > 0.05) between the median cyst 
229 weights of control groups (i.e. water and P407 control groups). Although the median 
230 weight of cysts recovered from ABZ-CMC and physical mixture groups were lower 
231 than those observed in the control groups, no differences were found between treated 
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232 groups and control groups (P > 0.05). In contrast, ABZ:P407 SDs treatment caused a 
233 significant decrease in the cysts weight compared with control groups (P < 0.05).
234 Metacestodes recovered from treated mice showed damage in the germinal 
235 layer, in relation to the control groups. However, the damage extension appears to be 
236 greater after ABZ:P407 SDs compared to the ABZ-CMC treatment (Fig. 2). 
237
238 Discussion
239 The drug of choice for the pharmacological treatment of human echinococcosis 
240 is ABZ. As this drug was developed primarily to target parasites in the gastrointestinal 
241 tract, a low bioavailability outside the intestine was considered important for its optimal 
242 performance. However, this feature is considered undesirable for a systemic parasitic 
243 disease as echinococcosis (Shuhua et al., 2002). The expression of a β-tubulin isoform 
244 with limited affinity to benzimidazoles by germinative cells and the low concentrations 
245 of ABZ reaching the parasite produce a parasitostatic effect and relapses after 
246 chemotherapy have been reported (Reuter et al., 2004; Brehm and Koziol, 2014).
247 The gastrointestinal permeability and solubility of some drugs are limiting 
248 conditions for oral absorption, directly affecting their bioavailability. Although 
249 permeability is an intrinsic property of a drug, different strategies have been developed 
250 for improving the dissolution rate with the aim of designing suitable formulations for 
251 oral administration (Vo et al., 2013). Scientific evidence indicates that a higher drug 
252 bioavailability correlates with an improved efficacy of benzimidazoles against murine 
253 echinococcosis (Mingjie et al., 2002; Shuhua et al., 2002; Dvorožňáková et al., 2004; 
254 Ceballos et al., 2006, 2008, 2009; Liu et al., 2012; Abulaihaiti et al., 2015; Hu et al., 
255 2019).
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256 The in vitro dissolution of a drug can be correlated with its bioavailability in vivo 
257 (Amidon et al., 1995). Simonazzi et al. (2018) demonstrated that the use of P407 as 
258 carrier in ABZ SDs markedly improved its solubility and dissolution rate compared 
259 with pharmaceutical grade ABZ and a commercial formulation. In addition, it was 
260 observed that the polymer maintained a desirable level of a supersaturation state in the 
261 dissolution medium. This was reached by preventing solvent-mediated crystallization 
262 over the time period necessary for the absorption process. The results observed in vitro 
263 with the ABZ:P407 SDs could be correlated with the efficacy obtained in the present 
264 study in the murine model of AE. 
265 During the chemoprophylactic efficacy study, all formulations of ABZ showed a 
266 tendency to decrease the development of E. multilocularis cysts. The ultrastructural 
267 study of metacestodes supports these results, showing the loss of cells of the germinal 
268 layer. However, no significant differences were detected between the median weight of 
269 cysts recovered from the treated mice. In contrast, Morris and Taylor (1988) reported 
270 that a significant protection against protoscoleces of E. granulosus was achieved in 
271 gerbils by one month treatment of ABZ  (10 mg/kg/day).
272 In the clinical efficacy study, the ABZ:P407 SDs achieved a statistically 
273 significant decrease in the weight of cysts, with an efficacy of 86%. In addition, the 
274 extent of damage caused by ABZ:P407 SDs was greater compared to the other treated 
275 groups. The ultrastructural alterations in the germinal layer were similar to those 
276 observed in mice infected with E. granulosus treated with other benzimidazoles 
277 (Ceballos et al., 2009, 2010). Our results are consistent with those reported by Pensel et 
278 al. (2014), who demonstrated a greater in vivo efficacy of ABZ formulated as SDs using 
279 P188 in the murine model of cystic echinococcosis.
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280 The SDs increase the dissolution rate of low water soluble drugs (Vo et al., 
281 2013). The enhanced efficacy obtained after oral administration of ABZ:P407 SDs 
282 could be explained by an increase in ABZ dissolution rate caused by the surfactant 
283 nature of poloxamers. Poloxamers in certain concentrations form micelles with a 
284 hydrophobic core which could incorporate insoluble molecules as ABZ, promoting 
285 faster and more complete solubility, increasing ABZ bioavailability and efficacy 
286 (Kabanov et al., 2002). On the other hand, the humectability effect of the surfactant 
287 could create a favorable microenvironment around the drug particles that would 
288 facilitate the dissolution process (Chen et al., 2004). In this way, poloxamers would 
289 improve water solubility and wettability of ABZ.
290 In terms of drug safety, ABZ has been extensively investigated in a wide range 
291 of antiparasitic indications. At low dose, the incidence of adverse experiences is low. At 
292 the higher doses and more prolonged exposure used in the treatment of echinococcosis, 
293 there is an increase in the number and severity of adverse experiences. Adverse effects 
294 include nausea, vomiting, diarrhea, dizziness, headache, neutropenia, liver toxicity, 
295 alopecia and others (Horton, 1997; Brunetti et al., 2010). The ABZ SDs formulations 
296 would allow administering lower doses of drug in the treatment of echinococcosis, with 
297 the consequent reduction in side effects. Paredes et al. (2018) reported ABZ self-
298 dispersible nanocrystals achieve the same efficacy against a model intestinal nematode 
299 parasite in dogs using a dose which was four times lower than a commercial 
300 formulation.
301 This pharmacotechnical strategy might in the future offer novel treatment 
302 alternatives for human AE. In a next step, we will characterize the pharmacokinetic 
303 profile after the administration of ABZ:P407 SDs in mice infected with E. 
304 multilocularis.
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482 Legends to figures
483
484 Fig. 1. Scanning electron microscopy of E. multilocularis cysts recovered from infected 
485 mice belonging to the chemoprophylactic efficacy study. (A) Control cyst with an intact 
486 germinal layer (gl). (B) Cyst recovered from mice treated with ABZ-CMC. Note the 
487 loss of cells in the germinal layer. (C) Cyst obtained from treatment with physical 
488 mixture. Observe the areas without cells. (D) Germinal layer of metacestode recovered 
489 from the ABZ:P407 SDs treated group. Areas with extensive loss of cells can be 
490 observed. Scale bar = 50 µm.
491
492 Fig. 2. Scanning electron microscopy of E. multilocularis cysts recovered from infected 
493 mice belonging to the clinical efficacy study. (A) Control cyst with an intact germinal 
494 layer (gl). (B) Cyst recovered from mice treated with ABZ-CMC. Reduction in the cell 
495 number could be observed. (C) Cyst obtained from treatment with physical mixture. 
496 Observe areas without cells. (D) Germinal layer of metacestode from ABZ:P407 SDs 
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501 Table 1 
502 Chemoprophylactic efficacy study. Median weight (g) and interquartile range (IQR) of 
503 the E. multilocularis cysts recovered from artificially infected mice from the 
504 unmedicated control and treated groups. Twenty-four hours post-infection, daily 
505 treatments were performed by intragastric administration of different formulations of 
506 ABZ at the dose of 25 mg/kg of ABZ over a period of 30 days.
Median weight 
of cysts (g)
 Interquartile range 
(IQR)
Water control 3.62 2.53
P407 control 2.91 4.81
ABZ-CMC 1.72 0.91
Physical mixture 1.05 1.53
ABZ:P407 SDs 0.95 1.78
507
508
509 Table 2 
510 Clinical efficacy study. Median weight (g) and interquartile range (IQR) of the E. 
511 multilocularis cysts recovered from artificially infected mice from the unmedicated 
512 control and treated groups. Six weeks post-infection, daily treatments were performed 
513 by intragastric administration of different formulations of ABZ at the dose of 25 mg/kg 
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Water control 4.27 2.41
P407 control 3.44 2.25
ABZ-CMC 0.69 0.72
Physical mixture 0.57 0.27
ABZ:P407 SDs 0.28* 0.66
516 * Statistically significant differences with the control groups (P < 0.05).
517
518
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Scanning electron microscopy of E. multilocularis cysts recovered from infected mice belonging to the 
chemoprophylactic efficacy study. (A) Control cyst with an intact germinal layer (gl). (B) Cyst recovered 
from mice treated with ABZ-CMC. Note the loss of cells in the germinal layer. (C) Cyst obtained from 
treatment with physical mixture. Observe the areas without cells. (D) Germinal layer of metacestode 
recovered from the ABZ:P407 SDs treated group. Areas with extensive loss of cells can be observed. Scale 
bar = 50 µm. 
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Scanning electron microscopy of E. multilocularis cysts recovered from infected mice belonging to the clinical 
efficacy study. (A) Control cyst with an intact germinal layer (gl). (B) Cyst recovered from mice treated with 
ABZ-CMC. Reduction in the cell number could be observed. (C) Cyst obtained from treatment with physical 
mixture. Observe areas without cells. (D) Germinal layer of metacestode from ABZ:P407 SDs treated group. 
Only cellular debris and isolated cells could be observed. Scale bar = 50 µm. 
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